Cidara Therapeutics, Inc. (CDTX)
Merck is acquiring Cidara Therapeutics for $9.2 billion, driving a significant stock surge. The company also received a BARDA award and FDA Breakthrough Therapy Designation for its influenza treatment.
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics, particularly for influenza.
Cidara Therapeutics, Inc. uses the ticker $CDTX for trading. Listed in the Stocks category.
Insights
- Cidara Therapeutics, Inc. (CDTX) market dominance near a 52-week low at [-------].
- Cidara Therapeutics, Inc. (CDTX) social dominance is up 676.67% from the previous week.
- Cidara Therapeutics, Inc. (CDTX) Galaxy Score™ is up 184.21% from the previous week.
- Cidara Therapeutics, Inc. (CDTX) creators is up 20.68% from the previous month.
- Cidara Therapeutics, Inc. (CDTX) mentions is up 17.06% from the previous month.
- Cidara Therapeutics, Inc. (CDTX) posts created is up 466.67% from the previous week.
Price: $221.40
Price 24-Hour Time-Series Raw Data
The stock price has surged dramatically, driven by the confirmation of a $9.2 billion acquisition by Merck, alongside a BARDA award, FDA Breakthrough Therapy Designation, and analyst upgrades. Increased social media discussions are amplifying these upward trends.
24-Hour: 0.03%
1-Year High: $221.40 on 2026-01-06
1-Year Low: $16.40 on 2025-04-04
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
Cidara Therapeutics, Inc. (CDTX) is currently AltRank #1,803 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [-----] [---]
[--] Month: [-----] +893
[--] Months: [-----] +1,644
[--] Year: [-----] +613
1-Year High: [-----] on 2026-02-05
1-Year Low: [--] on 2025-08-16
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +35
[--] Month: [--] +19
1-Year High: [--] on 2025-12-22
1-Year Low: [--] on 2026-02-01
Engagements: [---] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [------]
[--] Week: [------] +9.60%
[--] Month: [------] -62%
[--] Months: [---------] +94%
[--] Year: [---------] +1,738%
1-Year High: [---------] on 2025-11-14
1-Year Low: [--] on 2025-02-23
Engagements by network (24h): News: [--] X: [---] Reddit: [--] YouTube: [--] TikTok: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [---]
[--] Week: [---] +12%
[--] Month: [---] +17%
[--] Months: [-----] -22%
[--] Year: [------] +2,534%
1-Year High: [-----] on 2025-06-24
1-Year Low: [--] on 2025-04-13
Mentions by network (24h): News: [--] X: [--] Reddit: [--] YouTube: [--] TikTok: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Cidara Therapeutics, Inc. (CDTX) in the last [--] hours which is down 42% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [--] +14%
[--] Month: [---] +21%
[--] Months: [-----] -27%
[--] Year: [-----] +2,295%
1-Year High: [-----] on 2025-06-23
1-Year Low: [--] on 2025-04-13
The most influential creators that mention Cidara Therapeutics, Inc. in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @Unterhund70 | [--] | [--] | [--] | |
| @BiopharmIQ | [--] | [------] | [--] | [--] |
Sentiment: 67%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 67%
Daily Average: 81%
[--] Week: 80% -20%
[--] Month: 64% -4%
[--] Months: 64% -34%
[--] Year: 64% +14%
1-Year High: 100% on 2025-02-23
1-Year Low: 33% on 2025-03-13
Most Supportive Themes:
- Analyst Ratings: (10%) JP Morgan initiated coverage on Cidara Therapeutics with an Overweight rating and a $200 price target.
- BARDA Award: (8%) Cidara Therapeutics received a substantial BARDA award to support manufacturing and clinical development of CD388.
- FDA Breakthrough Therapy Designation: (7%) The FDA granted Breakthrough Therapy Designation to CD388 for the prevention of seasonal influenza.
Most Critical Themes:
- Valuation Concerns: (5%) Some analysts express concern about the current valuation of $CDTX, with one noting it seems expensive at a $4.3 billion market cap and that Phase [--] trials could fail.
Social Dominance: 0.00211%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00211%
Daily Average: 0.018%
[--] Week: 0.00233% +0.00203%
[--] Month: 0.005% -0.0025%
[--] Months: 0.005% -0.01%
[--] Year: 0.005% +0.002%
1-Year High: 0.384% on 2025-06-24
1-Year Low: 0.0002% on 2025-04-13
Market Dominance: 0.00789%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00789%
Daily Average: 0%
1-Year High: 0.241% on 2025-12-19
1-Year Low: 0.00779% on 2026-02-02
Top Cidara Therapeutics, Inc. Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"Even $FOLD had another suitor. The pressure on large pharmaceutical and biotech companies to acquire new assets is so high that bidding wars are becoming increasingly common. This is extremely bullish for the whole biotech sector. $XBI $AVDL $MTSR $CDTX Amicus reveals that it had another suitor before making a $4.8B deal to sell itself to BioMarin. https://t.co/7aXdgJuF57 Amicus reveals that it had another suitor before making a $4.8B deal to sell itself to BioMarin. https://t.co/7aXdgJuF57"
X Link @doepke_michel 2026-01-23T08:40Z [----] followers, [----] engagements
"☀ Updated list of TRIPLE & QUADRUPLE digits % gainer MULTI BAGGERS from me in last [--] yr ☀ $LAES - UP 2800+% $LUNRW - UP 1500+% $RKLB - UP 1200% $LITM - UP 1150% $OPTT - UP 1000+% $RR - UP 850% $ATNFW - UP 800% $GNPX - UP 700+% $CDTX - UP 650% $LUNR - UP 600+% $MOB - UP 600% $WKEY - UP 600% $AAOI - UP 550% $SKVI - UP 500% $GRI - UP 450% $HOVR - UP 400% $HOUR - UP 400% $HOVRW - UP 400% $SNOA - UP 375% $GNLX - UP 300+% $RNAZ - UP 300+% $EDBLW - UP 300+% $NUKK - UP 275% $IINN - UP 250% $TSSI - UP 250% $USAR - UP 225% $ALLR - UP 225% $CINGW - UP 225% $PRLD - UP 200+% $BMXI - UP 200+% $SOAR - UP"
X Link @SuperDuperInvst 2025-11-04T01:10Z 63.9K followers, 97.2K engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing